AGV Discovery SAS, in collaboration with scientists from Centre National de la Recherche Scientifique, Inserm and Universite de Montpellier, divulged azaindole derivatives acting as extracellular-regulated kinase (ERK) inhibitors, particularly ERK2, reported to be useful for the treatment of cancer, inflammation, autoimmune disease, substance abuse and dependence, metabolic syndrome, neurodegeneration, HIV infection, and pain, among other disorders.